Validation Cohort Demographics
The two new parameters were tested prospectively on a validation cohort
of twenty-nine consecutive patients (mean age 47.6 ± 18.8 years, 55.2%
male), of whom 21/29 (72.4%) had a RVOT SOO. As was observed in the
derivation cohort, those with a RVOT SOO were found to be of younger age
(42.4 ± 16.6 versus 61.1 ± 19.9 years, p = 0.016) and to have a higher
ejection fraction (55.1 ± 4.9 versus 45.9% ± 10.8, p = 0.047). There
was no significant difference in co-morbidity prevalence or AAD usage.
In those with a RVOT SOO, 21/21 (100%) had a LBBB VE. In the LVOT
cohort, the VE morphology was LBBB in 6/8 (75.0%), atypical RBBB in 1/8
(12.5%) and indeterminate in 1/8 (12.5%). The full baseline
characteristics of this cohort are shown in Table 3.